December 27, 2016: Alliqua BioMedical has exploded higher on FDA marketing approval for an ultrasound wound care system. The FDA 510K clearance decision date is noted as 12/22. Source: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K162721
November 8, 2016: Rodman & Renshaw/ H.C. Wainwright reiterates a Buy rating on Alliqua BioMedical and sets a price target of $2.50.
Alliqua BioMedical Stock Chart
Alliqua is a provider of advanced wound care solutions.
Trading The News: Alliqua BioMedical In The News
More Stock Picks
- Editas Medicine Patent Office Decision Favorable to Broad…
- Sell ACADIA Pharmaceuticals for a 15.8% Win
- Medtronic FDA Clears Expanded Indication for the OsteoCool…
- Protalix Biotherapeutics For a Monster 180% Win!
- Quantenna Communications Beats on Earnings and Revenue
- Valeant Pharmaceuticals Gets FDA Approval For Siliq…